食管切除术在IV期食管腺癌中可能发挥作用
该研究回顾性分析了66例初诊为临床IV期食管腺癌并接受食管切除术的患者,其中IV A期30例、IV B期36例。IV B期患者中26例为寡转移、10例为播散性。结果显示IV B期患者3年无进展生存率(56% vs 40%)和3年总生存率(85% vs 57%)均高于IV A期,调整后总生存也更高,提示对高度选择的晚期患者积极局部治疗可能获益。
要点
- IV期食管腺癌经高度选择后行食管切除术可能获益。
- IV B期寡转移患者先全身治疗再手术,3年OS达85%。
- IV A期患者标准新辅助治疗后手术,3年OS为57%。
核心结论
- 对高度选择的晚期或转移性食管腺癌患者,积极的局部治疗可能带来生存获益。
研究设计与样本
- 回顾性队列研究,从2010至2023年前瞻性维护数据库中纳入66例初诊临床IV期并接受食管切除术的食管腺癌患者。
主要发现
- 66例中IV A期30例(45%),IV B期36例(55%);IV B期中寡转移26例、播散性10例。
- IV A期患者3年无进展生存率为40%,IV B期为56%;3年总生存率IV A期为57%,IV B期为85%。
- 从治疗开始至手术的中位时间IV A期短于IV B期(P < .001)。
- 从治疗开始至最近随访的调整后总生存,IV B期患者更高。
临床怎么用
- 对高度选择的IV期食管腺癌患者,可在全身治疗基础上考虑食管切除术。
- IV B期寡转移患者可先全身治疗再评估手术;播散性患者化疗改善负担后可考虑手术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We sought to determine whether aggressive local treatment provides a benefit in patients with stage IV esophageal adenocarcinoma and to determine factors associated with survival. METHODS: Patients with clinical stage IV esophageal adenocarcinoma at diagnosis who underwent esophagectomy from 2010 to 2023 were identified from our prospectively maintained database. Clinicopathologic and demographic characteristics were compared among patients by stage. Overall survival was estimated using the Kaplan-Meier approach. RESULTS: In total, 66 patients met the inclusion criteria. Of these, 30 (45%) had stage IVA disease, and 36 (55%) had stage IVB disease. Of the 36 patients with stage IVB disease, 26 had oligometastatic disease, and 10 had disseminated disease. All patients with stage IVA disease received standard neoadjuvant therapy followed by curative-intent surgery; 26 of these patients (87%) received chemoradiation. Patients with oligometastatic stage IVB disease underwent systemic therapy with the goal of surgical resection. Patients with disseminated stage IVB disease underwent palliative chemotherapy, which led to improvement in disease burden and performance of esophagectomy. Median time from the start of therapy to surgery was shorter for patients with stage IVA disease than patients with stage IVB disease (P < .001). Three-year progression-free survival was lower for patients with stage IVA disease (40% vs 56%), as was 3-year overall survival (57% vs 85%). Adjusted overall survival, from the start of therapy to most recent follow-up, was higher for patients with stage IVB disease. CONCLUSIONS: Aggressive local treatment may provide a benefit for highly selected patients with advanced or metastatic esophageal adenocarcinoma.
引用
- Sewell M, Toumbacaris N, Tan KS, et al. Esophagectomy may have a role in stage IV esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2024. PMID: 39581309. doi:10.1016/j.jtcvs.2024.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。